Table 1.
Comparative results from frontline randomized clinical trials of imatinib 400 mg/day vs. second-generation TKIs for newly diagnosed CML in chronic phase
| Daily dose (mg) | Still on study therapy (years) | PFS (years) | OS (years) | MMR (years) | Median age, years (range) | Male (%) |
|---|---|---|---|---|---|---|
| Imatinib 400 | 50 (5) | 91 (5) | 92 (5) | 60 (5) | 46 (18–80) | 56 |
| 69 (3) | 91 (3) | 93 (3) | 55 (3) | 49 (18–78) | 63 | |
| 72 (1) | 90 (3) | 97 (3) | 44 (1) | 50 (19–89) | 59 | |
| 80 (1) | 93 (1)a | 97 (1) | 32 (1) | 47 (18–89) | 54 | |
| 73 (3.5) | 94 (3) | 95 (3) | 79 (3) | 54 (16–88) | 60 | |
| NR | 80 (4) | 90 (4) | 36 (1) | 50 (23–80) | 63 | |
| Nilotinib 300 BID | 60 (5) | 92 (5) | 94 (5) | 77 (5) | 47 (18–85) | 56 |
| Dasatinib 100 | 71 (3) | 91 (3) | 94 (3) | 69 (3) | 46 (18–84) | 56 |
| 80 (1) | 93 (3) | 97 (3) | 59 (1) | 47 (18–90) | 60 | |
| Bosutinib 500 | 71 (1) | 94 (1)a | 99 (1) | 47 (1) | 48 (19–91) | 60 |